XML 41 R31.htm IDEA: XBRL DOCUMENT v2.3.0.15
Acquisitions (Details) (USD $)
3 Months Ended9 Months Ended
Sep. 30, 2011
Mar. 31, 2011
Sep. 30, 2010
Mar. 31, 2010
Sep. 30, 2011
Sep. 30, 2010
Jan. 05, 2011
Dec. 31, 2010
Sep. 30, 2011
United States [Member]
Sep. 30, 2011
Segment, Geographical, Groups of Countries, Group One [Member]
Sep. 30, 2011
Segment, Geographical, Groups of Countries, Group Two [Member]
Sep. 30, 2011
Japan [Member]
Jan. 04, 2011
Sadra Medical, Inc. [Member]
Jan. 05, 2011
Intelect Medical, Inc., [Member]
Feb. 15, 2011
ReVascular Therapeutics, Inc. [Member]
Mar. 03, 2011
Atritech, Inc. [Member]
Mar. 31, 2011
2011 Acquisitions [Member]
Sep. 30, 2011
Pre-2009 Acquisitions [Member]
Sep. 30, 2011
Post-2008 Acquisitions [Member]
The components of the preliminary purchase price as of the acquisition date for acquisitions consummated in the first quarter of 2011 are as follows                   
Payment to acquire in cash            $ 193,000,000$ 60,000,000$ 19,000,000$ 98,000,000$ 370,000,000  
Fair value of contingent consideration                287,000,000  
Prior investments                55,000,000  
Total                712,000,000  
The preliminary purchase price allocation:                   
Goodwill271,000,000   271,000,000   158,000,000105,000,0007,000,0001,000,000       
Amortizable intangible assets97,000,000   97,000,000              
Indefinite-lived intangible assets468,000,000   468,000,000              
Deferred income taxes(124,000,000)   (124,000,000)              
Total712,000,000   712,000,000              
Additional Acquisitions (Textuals) [Abstract]                   
Payment to acquire in cash            193,000,00060,000,00019,000,00098,000,000370,000,000  
Percentage of equity acquired            86.00%85.00%100.00%100.00%   
Future acquisition related consideration contingent upon the achievement of certain revenue-based milestones            193,000,000016,000,000275,000,000 260,000,000760,000,000
Aggregate carrying value of equity interest in Sadra and Intelect prior to acquisition of remaining equity      11,000,000            
Risk-adjusted discount rate for contingent consideration 2.00%                 
Risk adjusted discount rate for contingent consideration, high 20.00%                 
Note receivable from acquired company prior to acquisition      6,000,000            
Acquisitions (Textuals) [Abstract]                   
Gains on previously held equity interests 38,000,000                 
Business combination, liabilities arising from contingencies, amount recognized376,000,000287,000,000  376,000,000  71,000,000           
Estimated fair value of prior equity ownership interest in Sadra and Intelect                55,000,000  
Adjustments to contingent consideration expense for current period acquisitions3,000,000   12,000,000              
Adjustments to contingent consideration expense for prior period acquisitions3,000,000   6,000,000              
Milestone payment   250,000,000 250,000,000             
contingent consideration payment related to prior period acquisition    $ 0$ 4,000,000